RNAseq analysis of BRCA deficient tumors treated with saline, Nano-Talazoparib or Talazoparib

We report the gene expression profile in BRCA deficient tumors after treatment with saline, nanoparticle-formulated Talazoparib and free Talazoparib To study the regulation of gene expression after treatment with the PARP inhibitor Talazoparib in BRCA deficient breast cancer, Brca1Co/Co;MMTV-Cre;p53+/- mice were used in this study. Treatment was started when a tumor was 4-5 mm in diameter. Tumors from Brca1Co/Co;MMTV-Cre;p53+/- mice treated with saline, free Talazoparib (i.v.), or NanoTLZ for five doses (0.33mg/kg, three times a week) were harvested. Three samples were collected for each group. Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA). The RNA integrity number (RIN) was detected using the Aligent Bioanalyzer at the MSU Research Technology Support Facility (RTSF) Genomics Core facility. RNAseq and the bioinformatics analysis were performed by Novogene (Sacramento, CA).